Xencor Inc stock is traded at $35.03, with a volume of 2,409,033. It is up +14.33% in the last 24 hours and up +41.02% over the past month. Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Previous Close:
$30.64
Open:
$31.12
24h Volume:
2,409,033
Relative Volume:
1.06
Market Cap:
$2.60B
Revenue:
$97.36M
Net Income/Loss:
-$172.42M
P/E Ratio:
-
EPS:
-$2.30
Net Cash Flow:
-$188.84M
1W Performance:
+16.81%
1M Performance:
+41.02%
6M Performance:
+162.20%
1Y Performance:
+155.69%
1-Day Range:
$30.86$35.05
1-Week Range:
$28.61$35.05
52-Week Range:
$10.38$35.05
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor IncSector
HealthcareIndustry
BiotechnologyPhone
626-305-5900Address
465 N. HALSTEAD ST., PASADENA, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS